Key result
Maternal administration of high-dose oral amiodarone successfully treated fetal ventricular tachycardia and non-immune hydrops fetalis, with the child surviving and healthy at 3 years of age.
Case Report (n=1)
Maternal administration of amiodarone can be an effective treatment for fetal ventricular tachycardia complicated by hydrops fetalis.
May support amiodarone consideration in refractory fetal VT with hydrops; case report leaves open need for prospective safety and efficacy data.
Fetal cardiac arrhythmias are one of the causes of intra-uterine congestive heart failure and non-immune hydrops fetalis leading to fetal death. As ventricular tachycardia (VT) is rarely diagnosed in utero, it leads to emergency deliveries. We report a prenatal diagnosis of fetal tachycardia at 20 weeks of gestation associated with non-immune hydrops fetalis. The tachycardia seemed to be supraventricular and was initially treated by digoxin and sotalol. The hydrops increased and sotalol was stopped in order to give the mother a high dose of amiodarone by mouth over a long period. Although the tachycardia, which the ECG recorded at birth revealed to be of ventricular origin, persisted but at a lower rate, the new treatment proved successful. The child is three years old now and health, though with persistent VT. In conclusion, fetal tachycardia with similar ventricular and atrial rates can be a VT and the drug of choice in this case seems to be amiodarone.
No takes yet. Share an insight, caveat, or question.
Schleich et al. (2000) conducted a case report in Fetal ventricular tachycardia with non-immune hydrops fetalis (n=1). Amiodarone was evaluated on Survival and clinical status. Maternal administration of high-dose oral amiodarone successfully treated fetal ventricular tachycardia and non-immune hydrops fetalis, with the child surviving and healthy at 3 years of age.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: